FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for the treatment or prevention of cancer in a subject. The proposed method includes the administration to a subject of effective amount of an antibody with binding specificity of a T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and an immunotherapeutic agent containing an antibody against human NRP, and it effectively inhibits the tumor growth.
EFFECT: obtaining a method for the treatment or prevention of cancer.
22 cl, 3 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIGEN-BINDING PROTEINS AGAINST GITR AND METHODS OF THEIR USE | 2017 |
|
RU2795625C2 |
| ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY | 2012 |
|
RU2715642C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
